Individualizing salvage regimens: The inhibitory quotient (Ctrough/IC50) as predictor of virological response

AIDS

Volumn 17, Issue 2, 2003, Pages 262-264

  Casado, Jose L ^a   Moreno, Ana ^a   Sabido, Raquel ^a   Martí Belda, Paloma ^a   Antela, Antonio ^a   Dronda, Fernando ^a   Perez Elías, María J ^a   Moreno, Santiago ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; INDINAVIR; NELFINAVIR; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; VIRUS LOAD;

DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; SALVAGE THERAPY;

EID: 0037462633     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200301240-00019     Document Type: Article

References (10)

1. Hirsch MS, Conway B, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 1998, 279:1984-1991.
2. Condra JH, Petropoulos CJ, Ziermann R, Schleif WA, Shivaprakash M, Emini EA. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J Infect Dis 2000, 182:758-765.
3. Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, van Cauwenberge A, et al. A rapid method for simultaneous detection of phenotypic rsistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998, 42:269-276.
4. Taylor S, Pereira A. Penetration of HIV-1 protease inhibitors into CSF and semen. HIV Med 2000, 1 (Suppl. 2):18-22.
5. Kawle SP, Remmel RP, Weller OD, Fletcher CV. A simultaneous HPLC assay for quantification of indinavir, saquinavir, ritonavir, and nelfinavir in human plasma. In: 5th Conference on Retroviruses and Opportunistic Infections. Chicago. February, 1998 [Abstract 121].
6. Montaner J, Hill A, Acosta E. Practical implications for the interpretation of minimum plasma concentrations/inhibitory concentration ratios. Lancet 2001, 357:438-440.
7. Kempf D, Hsu A, Jiang P, Rode R, Hertogs K, Larder B, et al. Response to ritonavir intensification in indinavir recipients is highly correlated with virtual inhibitory quotient In: 8th Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [Abstract 523].
8. Molla A, Kempf D, Hsu A, Mo H, Jun E, Japour A, et al. Use of inhibitory quotient (IQ) to estimate the activity of HIV protease inhibitors. In: HIV DART 2000 - Frontiers in Drug Development for Antiretroviral Therapies. Puerto Rico, December 2000 [Abstract 009].
9. Dieleman JP, Gyssens IC, van der Ende M, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999, 13:473-478.
10. Gatell JM, Lange J, Arnaiz JA, Fatkenheuer G, Mallolas J, Clotet B. A randomized study comparing continued indinavir (800 mg tid) to indinavir/ritonavir (800/100 mg bid) in HIV patients having achieved viral load with indinavir plus two nucleosides analogues: the BID efficacy and safety trial (BEST). In: XIIIth International AIDS Conference. Durban, South Africa, 9-14 July 2000 [Abstract WeOrB484].